Thomas A. Mitro
2017
In 2017, Thomas A. Mitro earned a total compensation of $4.6M as President and Chief Operating Officer at Aerie Pharmaceuticals, a 182% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $275,150 |
|---|---|
| Option Awards | $2,534,808 |
| Salary | $423,308 |
| Stock Awards | $1,390,468 |
| Total | $4,623,734 |
Mitro received $2.5M in option awards, accounting for 55% of the total pay in 2017.
Mitro also received $275.2K in non-equity incentive plan, $423.3K in salary and $1.4M in stock awards.
Rankings
In 2017, Thomas A. Mitro's compensation ranked 2,119th out of 14,666 executives tracked by ExecPay. In other words, Mitro earned more than 85.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,119 out of 14,666 | 86th |
Division Manufacturing | 722 out of 5,768 | 88th |
Major group Chemicals And Allied Products | 195 out of 2,074 | 91st |
Industry group Drugs | 148 out of 1,730 | 91st |
Industry Biological Products, Except Diagnostic Substances | 31 out of 316 | 90th |
Source: SEC filing on April 27, 2018.
Mitro's colleagues
We found three more compensation records of executives who worked with Thomas A. Mitro at Aerie Pharmaceuticals in 2017.
News
Aerie Pharmaceuticals CEO Vicente Anido's 2021 pay rises 4% to $3.8M
April 26, 2022
Aerie Pharmaceuticals CEO Vicente Anido's 2020 pay falls 35% to $3.6M
April 27, 2021
Aerie Pharmaceuticals CEO Vicente Anido's 2019 pay slips 18% to $5.5M
April 24, 2020
Aerie Pharmaceuticals CEO Vicente Anido's 2018 pay falls 33% to $6.8M
April 10, 2019